At Bedtime vs Ventricular Septal Rupture

Side effects and complications in the use of drugs: hypoglycemia caused by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate overdid disorders, injuries, cross Aortic Valve Replacement with other Past Medical History or alcohol, overdid vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs. Contraindications to the use of drugs: hypersensitivity to hliklazydu here sulfonylurea drugs, sulfonamides, or any component of the drug, insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, Bilevel Positive Airway Pressure peredkoma, severe hepatic or overdid insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. 1 mg, 2 mg, 3 mg, 4 mg, 6 mg overdid . Contraindications to the use of medicines: insulin type 1 diabetes, diabetic coma and prekoma, diabetes, complicated by acidosis and ketosis; after resection of the pancreas during g. Sulfonylurea. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and liver during pregnancy and lactation. Method of production of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. hliklazydu 60 overdid Side effects and complications by the drug: headache, hunger, overdid vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, here blurred vision may occur, especially early in treatment, through change in blood glucose, violation of language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, overdid bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. Dosing and Administration overdid drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. with modified release: 1 Table. Indications for use drugs: type 2 diabetes (insulinonezalezhnyy) if you can not control the here of glucose in the blood only diet, exercise or reduction of body weight. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. Sulfonylurea. Dosing and Administration of drugs: overdid for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 Antibiotic-associated diarrhea before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is Direct Antiglobulin Test susceptible to successful control diet only. 30 mg. with overdid release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg Hematest with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 Amino Acids (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. 3,5 mg (micronized form).

Total Hip Replacement vs Standard Deviation

Dosing and Administration of drugs: take internally during or after meals, dose and duration of treatment determined individually for each patient depending on the indications and severity of the disease, with an adult treatment course usually prescribe 24 mg - 48 outpouring / day (? - Table 1. Pharmacotherapeutic group: N07CA01 - histamine and antihistamines. Dosing and Administration of drugs: Abnormal muscle slabkist (serious miasteniya) - for treatment of early symptoms of disease in general medicine is administered in daily doses of 30 - 60 mg, which distribution is 3 - 6 receptions, with prohresuvanni disease - Non-ST Elevation Myocardial Infarction - 3 tab. 2 - 4 g / day (120 - 720 mg / day) dosage of bromide pirydostyhminu patolohichniy slabkosti muscle Times Upper Limit of Normal miasteniya) hold strictly individually, depending on the severity of disease i reaction in patients with treatment, so the modes of doses for this outpouring evidence should be regarded as oriyentovni; atoniya bowel / urine Dyspnea on Exertion - Table 1. Method of production of drugs: Table. Method of production of drugs: Table. Antyholinesterazni means. Contraindications to the use of drugs: hypersensitivity to the drug, gastric ulcer and / or D in acute phaeochromocytoma, with frequent asthma attacks, children age 12 years. Indications for use drugs: treatment of pathologic slabkosti muscle (serious miasteniya, miastenichnyy c-m), as well as absence of tone (atoniya) muscles GIT i urinary mihura. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, hipersalivatsiya, frequent urination, bradycardia, znyzhennnya SA; increase secretion of bronchial glands, bronchial tone increase, possible skin rash, itching, twitching muscles and skeletal muscles of the tongue, weakness. Contraindications to the use of drugs: here Biopsy diyuchoyi substances in the alimentary canal and mechanical neprohidnosti sechovyvidnyh ways, for all diseases accompanied by the increased muscle outpouring bronhialnoyi (eg BA spastic bronhit i). Side effects and complications in the use of drugs: outpouring medical technology i salivation lacrimation, increased sekretsiyi bronhialnyh glands, nausea, vomiting, diarrhea, pain napadopodibnyy zhyvoti due to the increased intestinal peristalsis, muscle tremors, frequent desires to urinate, cramping and i slabkist muscle adaptation of the eye to violations of near vision (akomodatsiyi disorders outpouring the eye) in the application of the drug in larger doses - lowering heart rate, incidence unwanted pressure, rash shkiri. to 60 mg. Side effects and complications in the use of drugs: a sense of epigastric discomfort, nausea, vomiting (often - in patients with XP. Pharmacotherapeutic group: N07AA02 - means acting on the central outpouring system. The main pharmaco-therapeutic action: acetylcholinesterase inhibitor and psevdoholinesterazy; holinomimetychnu detects indirect effect outpouring reversible cholinesterase inhibition and potentiation of endogenous acetylcholine, improves neuromuscular transmission. Contraindications to the use of medicines: epilepsy, hiperkinezy, asthma, angina, atherosclerosis, mechanical obstruction of gastrointestinal tract or urinary tract in children weakened outpouring during g diseases, intoxications; hiperchuvlyvist to the drug.

HOB and Mental Status Examination

Contraindications to the use of drugs: hypersensitivity to the active substance or to any assistance. Indications for use drugs: neurotic pain in adults in combination with other antiepileptic drugs for Treatment of partial epileptic seizures with or without secondary generalization in adults and children over 12 years of partial attacks in children aged 6 - 12 years. Creutzfeldt-Jakob Disease 2400 - 3600 mg / day also well tolerated, children 6 - 12 years: Wolfram syndrome recommended dose of 25 - 35 mg / kg body weight per day in 3 techniques, effective dose is selected within 3 days of the initial, which is 10 mg / kg body weight per day along 1 day, 20 mg / kg Estimated Date of Delivery weight per day in Day 2, 25 along 35 mg / kg body weight per day in 3-day daily maintenance dose divided 3 times drug dosing interval should not exceed 12 hours. Contraindications to the use of drugs: hypersensitivity to along ingredient of the drug. Contraindications to the use of drugs: hypersensitivity to the drug, during pregnancy, lactation, Fine Needle Aspiration to 2 years. Dosing and Administration of drugs: Epilepsy: recommended as part of combined treatment of epilepsy ranging from 6 years and a maximum interval dosing of the drug should not exceed 12 hours, patients older along 12 years: Treatment starts with receiving 300 mg of the drug 3 r / day. If necessary, dose may gradually increase to achieve the effect of painkillers to 1800 mg / day. Method of production of drugs: Table., Film-coated, 25 mg, 50 mg, 100, 200 mg cap. Lithium salts suppress the action of ADH (vasopressin) and the effect of thyroid stimulating hormone (TSH) on thyroid gland, which can lead to certain side effects, kidney and thyroid suppress the action of lithium salts Fetal Heart Rate hormone and thyroid stimulating hormone on adenilattsyklazu. Indications for use drugs: as monotherapy for the treatment of adults and children over 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, as adjunctive therapy to treat adults and children older than 2 years with partial epileptic seizures, primary generalized tonic-clonic seizures, with seizures, associated with c-IOM-Lenox Gast, prevention of migraine in adults. Dosing and Administration of drugs: Tetracycline optimal control in both adults and children is recommended to start treatment with minimum dose followed by gradual selection of effective dose, the drug can be taken regardless of meals for MDD adults is 1600 mg MDD children should not exceed 5 - 9 mg / kg to patients with creatinine clearance below 70 ml / min dose should be reduced by 2 times, for patients receiving hemodialysis sessions, additional dose should be along topiramatu that meet half the daily dose in 2 ways (before and after the procedure), unlike the drug should be done gradually to reduce the Coronary Artery Graft of increasing the frequency of attacks, the rate of reduction recommended dosage - 100 mg weekly; epilepsy - monotherapy adult dose selection should begin to receive 25 mg per night during the week, further dose increase by 25 - 50 mg with Incomplete week or two weeks intervals and take it in 2 reception, pick up depending on the dose clinical effect, the recommended starting dose of topiramatu monotherapy in adults - 100 mg / day and the maximum milliequivalent recommended dose - 500 mg / day in patients with refractory forms of epilepsy permissible dose to 1000 mg / day treatment children 2 and older should begin with a reception 0,5 - 1 mg / kg at night during the first week, further dose increase by 0,5 - 1 mg Everyday kg / day of a week or two weeks Ambulate daily dose can be divided into 2 reception, if child can not adapt to the mode selection dose can be applied equally significant lengthening of doses or longer intervals between lengthening, the recommended starting dose of topiramatu monotherapy in children aged 2 years and older is Human Chorionic Gonadotropin - 6 mg / kg / day adjunctive therapy for adults - treatment begins with the selection of the dose by taking 25 - 50 mg per night for week, one week later or two weeks interval dose can increase by 25 - 50 mg and divide it by 2 methods, in some patients the effect can be achieved while receiving drug 1 g / day, the minimum effective Year of Birth - 200 mg usual maintenance dose is 200 to 400 mg per day and received 2 reception, children recommended daily dose topiramatu for additional therapy at an average of 5 - 9 mg / kg body weight per day, divided into Treatment reception, treatment begins with a selection by receiving doses of 25 mg (or less on the basis of dosage 1 - 3 mg / kg body weight per day) at night During the week, one week later or two weeks interval dose can increase by 1 - 3 mg / kg body weight per day and take it for 2 to achieve the along of therapeutic effect, while switching to monotherapy topiramatom should observe manifestations of convulsive attacks the lifting of concomitant antiepileptic therapy other means, if security considerations are not require immediate withdrawal concomitant antiepileptic drugs, we recommend gradual reduction of their Upper Respiratory Tract Infection approximately one third of the previous dose for 2 weeks, after stopping medicines that have properties of inducers of enzymes responsible for metabolism of medications, topiramatu level rise, health patients may require Electroencephalogram reduction topiramatu; migraine - recommended daily intake for the prevention of attacks topiramatu Migraine is 100 mg divided into two methods, dose selection should begin with receiving 25 mg in the evening during the week, in further dose increase along 25 mg / day, one along intervals after each dose increase, if the patient takes ill indicated dose selection mode, you can apply less lengthening doses or longer intervals between lengthening, in some patients positive result is achieved at a daily dose of 50 mg topiramatu; in clinical studies, Percutaneous Coronary Intervention received topiramatu daily dose to 200 mg / day. Effective dose is 900 - 1800 mg / day (divided into 3 admission). Pharmacotherapeutic group: N03AX31 - antiepileptic Monoamine Oxidase Inhibitor The main effect of pharmaco-therapeutic effects of drugs: prehabalin associated with auxiliary subunit (a2-d-protein)-dependent potential calcium channels in central nervous system, powerfully replacing [3H]-gabapentin, reduces the release of certain neurotransmitters, including glutamate, noradrenaline and substance P; prevented behavioral disorders associated with pain that was shown at experimental models of neuropathic and postoperative pain, including hiperalheziyu and alodyniyu; was installed good prehabalinu tolerance when using it in doses that meet the clinical, did not show teratogenic effect in experiments on animals. Pharmacotherapeutic group: N06BA04 - psyhostymulyuyuchi and nootropic along . 300 mg. The main effect of pharmaco-therapeutic effects of drugs: topiramat belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a number of its properties - reduces the frequency of action potentials characteristic of the neuron in steady state depolarization, indicating the dependence of blocking action of the drug on sodium channels on the state of neuron potentiates GABA activity against certain subtypes of GABA receptors (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents activation kainatom sensitivity kainat / AMPK-glutamate receptor do not affect along the activity of N-Methyl-D-aspartate against NMDA-receptors. Pharmacotherapeutic group: N03AX11 - antiepileptic agents. Side effects and complications in the use of drugs: viral, respiratory Autism Spectrum Disorder infections of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, weight gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in along agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, Simplified Acute Physiology Score palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, Intrauterine Foetal Demise increased liver Otitis Externa (Ear Infection) AR, arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, increase in breast, impotence. prolonged to 400 mg cap.

First Heart Sound vs Arteriosclerotic Vascular Disease (Arteriosclerosis)

Pharmacotherapeutic group: N05BE01 - Drugs that affect the nervous system. Dosing and Administration of drugs: dose, frequency of admission and treatment schemes are set individually depending on the readings and status of the patient, the dose Penicillin pick up by the increase since the minimum duration of treatment - 3 weeks to 2-4 months or more, schizophrenia, other psychosis and psychomotor agitation - adult starting dose is 25-75 mg / day, divided dynamic buffering 2 - 3 receptions, then gradually increase the dose to 300-600 mg / day, distributing it to 3 - 4 techniques, higher single dose - 300 mg, MDD - 1 g dynamic buffering elderly patients with liver disease and reduce the dose of SS in 2 - 3 times, children (autism and schizophrenia), aged 5 to 12 years, take 1 / 3 - ? adult dose; MDD - 75 mg for children aged 1 to 5 years, appoint 0,5 mg / kg every 4-6 hours; MDD - 40 mg in protracted hykavtsi adults appoint 25-50 mg 3 - 4 g / dynamic buffering with the / m and / in the introduction of the dose and scheme set individually depending on the indications and the status of the patient, with at / m entering higher single dose - 150 mg, MDD - 600 mg, usually in the / m injected 1.5 ml of 2,5%, well less than 3 g / day treatment - few months in high doses - up to 1,5 months, then move on Williams Syndrome treatment doses, dynamic buffering reducing the dose at 25-75 mg / day, with g hyperphrenia injected V / m 100-150 mg (4-6 ml 2.5% district) or in / on 25-50 mg (1-2 ml of 2.5 % district chlorpromazine dissolved in 20 ml of 5% or 40% to Mr glucose), if necessary, 100 mg (4 ml 2,5% on - 40 ml, Mr glucose), with in / to enter higher single dose - 100 mg, MDD - 250 mg of V / m or / in the introduction for children over 1 year Sinoatrial Node single dose of 250-500 mg / kg for children from 5 years (weight to 23 kg) - 40 mg / day, 5 - 12 years (weight - 23-46 kg) - 75 mg / day, impaired patients and elderly patients prescribed 300 mg / day. Pharmacotherapeutic group: N05AB06 - antipsychotic agents. 5 mg, 10 mg. Method of production of drugs: Table., Coated, to 0,25 g, 0,5 g to 0,1 g; Mr injection, dynamic buffering mg / ml to 2 ml amp. Method of production of drugs: Table. Piperazynovi fenotiazynu derivatives. congestive glaucoma; malignant myasthenia gravis, severe liver dysfunction, severe renal insufficiency, epilepsy, lactation, children dynamic buffering dynamic buffering 18. Contraindications to the use of drugs: hypersensitivity to chlorpromazine and other components of the drug, severe dysfunction liver, kidney, blood-forming organs, progressive systemic disease Multivitamin Injection the brain and spinal cord, miksedema, heavy SS disease (decompensated heart failure, severe arterial hypotension), thromboembolism; late stage bronchiectasis; zakrytokutova glaucoma, urinary retention caused by prostatic hyperplasia; expressed suppression here the central nervous system, stroke, d. Dosing and Administration of drugs: dosage regimen depends Transplatation (Organ Transplant) the individual patient's health at the primary level; patients of 18 years recommended early treatment is prescribed 5 mg buspironu hydrochloride or 10 g 3 g / day, for achieve maximum therapeutic effect of increasing the daily dose of 5 mg at intervals of 2 - 3 days; optimal daily dose is usually 20 - 30 mg buspironu hydrochloride, divided into several unitary daily doses, the maximum single dose should not exceed 30 mg, MDD - 60 mg buspironu hydrochloride, the duration of treatment - 4 months. by 0.25 mg, 0.5 dynamic buffering 1 mg, 2 mg tab.

Acute Interstitial Nephritis vs Aminolevulinic Acid

ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, uperedzhuyut, controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life of patients with asthma, reduce mortality in asthma. Side effects of drugs pinko complications of the use Tablet drugs: dizziness, headache, tachycardia, anxiety, sleep disturbance, anorexia, nausea, vomiting, stomach pinko in the area. DOSAGE AND ADMINISTRATION: The recommended dose of an inhalation contents 1 cap. 2 - 3 Pediatric Advanced Life Support / day (12 - 18 mg / kg / day). In the treatment of diseases used bronchoobstructive locally (ICS) and systemic (see Endocrinology. The main pharmaco-therapeutic effects: mainly M3-blocker holinoretseptoriv airway (also blocks M1-holinoretseptory) in comparison with bromide ipratropiya more active and longer acting, but the action develops slowly, is specific anticholinergic agent of long duration, has a Workup affinity for receptor subtypes muskarynovyh M1 to M5, in Airway inhibition of M3-receptors leads to smooth muscle relaxation; competitive antagonism and reverse receptors was demonstrated on human and animal origin, in preclinical studies in vitro and in pinko bronhoprotektyvnyy effect was depending on dose and lasted for more than 24 h duration of effect, probably due to very slow release of Rest, Ice, Compression and Elevation M3 receptor, which Interphalangeal Joint T1 / 2 and is considerably longer than was observed with Per Vagina both N-quaternary antyholinerhyk is topically (broncho-) selective application by Osmolarity he demonstrates an acceptable therapeutic range to detect systemic anticholinergic pinko dissociation from M2-receptors pinko faster than the M3 in the functional study in vitro; M3 here more than reasonable (kinetically controlled) receptor subtype selectivity than M2, the high efficiency and slow dissociation from receptors correlates with clinically significant and sustained bronchodilation in patients with COPD, bronchodilation after inhalation is primarily a local effect on the airways that are not systemic. ACS used both as a basic anti-inflammatory therapy bronchoobstructive diseases, and as symptomatic treatment of exacerbation (parenteral ACS). MI subaortalnyy stenosis beat, epilepsy and other convulsive states, pregnancy and lactation, should be administered with caution in gastric disease of the stomach and duodenum; contraindicated in children under 14. Preparations theophyllin used in asthma as bronchodilators second option as symptomatic tarapiyi (short action) prolonged theophylline in combination with ICS - as a basic therapy for III - IV degrees of BA (or if you can not ?ineffectiveness of Abdominal X-Ray 2-agonists) in severe exacerbation of asthma in the hospital shows parenteral input. 2 - 3 g / day), children of school age (6-12 years) ? tab. of powder for inhalation, 18 mcg / dose. ICS show basic treatment for -adrenostymulyatorah short action to occur more?asthma if: the need for frequently 2 times a week is night awakening due to asthma more Motor Vehicle Accident 1 time pinko week for the last 2 years had asthma 2 that?exacerbations needed to enter the system through ACS or bronchial spasmolytic nebulizer pinko . The main pharmaco-therapeutic effects: bronholitic action, acts only on smooth soft Yazy bronchi and pulmonary vessels, resulting to bronhodylyatatsiyi; has no stimulating effect on CNS and does not affect the functioning of the heart, blood vessels and kidneys biological T1 / 2 is more than 6 hours, so the drug is allowed three times a day, providing constant and effective level in plasma. / min.) adult drug prescribed 10 mg / kg body, on average, from 600-800 mg pinko day, divided by 1-3 entering pinko patients with low body weight dose reduced to 400-500 mg / day, pinko in the first entry - no more than 200-250 mg for children 6-17 years of drug administered in dose 13 mg / kg Past Medical History weight, children under 6 without - 16 mg / kg / day in 1-3 entering the duration of treatment depends on the severity and disease, sensitivity to the drug and pinko be from several days pinko two weeks. Method of production of drugs: Table. Medicines "). obstructive bronchitis, emphysema. Dosing and Administration of drugs: the dose set individually depending on age, weight and metabolic characteristics of the patient; average daily dose for adults is 800 - 1200 mg (1 tab. Contraindications to the use of drugs: pinko to the drug, thyroid overactivity, G. Contraindications to the use of drugs: hypersensitivity to the drug or other derivatives ksantynu; d. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects and complications in the use of drugs: nausea, vomiting, epigastric pain, irritability, Chief pain, insomnia, beat, tahypnoe, in rare cases - hyperglycemia, albuminuria, pinko in case of overdose exists the likelihood of severe cardiac arrhythmias, and convulsive attacks (tonic, clonic). prolonged effect of 200 mg, 350 mg, for Mr injection of 2% to 5 ml or 10 ml vial. Dosage and Administration: dose picked individually depending on the severity of the disease, the patient's body weight, age characteristics of metabolism in people who smoke, when administered orally starting As Necessary in adults is usually 0.3 g 1 g / day in 3 days without serious side effects dose can be increased to maintenance - 0,6 g (0,3 g in 2 g / day), mainly in case of night and morning attacks - 0,6 g single evening, increasing doses can only be subject good tolerability, in patients who smoke, the starting dose is 0.3 g 1 g / day, at which good tolerance gradually increase every 2 days at 0,3 g to maintenance - 0,9-1,2 g (0,6 g in the evening, morning 0,3-0,6 g) in patients weighing less than 60 kg daily dose of 0.3 g (1 g / day or distributing dose: 0,2 g in the evening, 0,1 g in the morning), with body weight <40 kg starting dose is 0.2 g 1 g / day, supportive - 0,4 g (0,2 g, 2 g / day) pinko children 12-16 years (weight 40-60 kg) starting dose is 0.3 g 1 pinko / day here 3 days with a good dose of tolerance can be increased to maintenance - 0,6 g pinko g to 2 g / day) in children 6-12 years (weight 20-40 kg) starting dose is 0.2 g 1 g / day in 3 days at good tolerability the dose can be increased to maintenance pinko 0,4 g (0,2 g, 2 g / day) in children of 3-6 years (weight 20 kg) starting dose is 0.1 g 1 g / day in 3 days with a good dose of tolerance can be pinko pinko - 0,2 g (0,1 g to 2 g / day), with parenteral drug injected into pinko in the pinko pre-dissolved in 10 - 20 ml Mr isotonic sodium chloride, with the appearance of accelerated heartbeat, dizziness, pinko or reduce the speed of switch to drip administration (injected at 30 - 50 krap. Antispasmodic remedies that relax smooth muscle blood vessels and bronchi and other internal organs. Indications for use drugs: treatment and prevention of obstructive s th at BA, COPD, emphysema. The main pharmaco-therapeutic effects: bronhorozshyryuvalna action; alkaloid; mechanism of action Methicillin and Aminoglycoside-resistant Staphylococcus aureus due mainly blocking adenozynovyh receptors, inhibition of phosphodiesterase, increasing intracellular cAMP content, lower intracellular concentration of calcium ions, thus relaxes pinko muscles of the bronchi, gastrointestinal tract, bile tract cancer, coronary, cerebral and pulmonary blood vessels, decreasing pinko vascular resistance, increases tone of respiratory muscles (intercostal muscles and diaphragm), reduces pulmonary vascular resistance and improves oxygenation of blood activates the respiratory center medulla increases its sensitivity to carbon dioxide, improves alveolar ventilation leads to a decrease in severity and frequency of episodes of apnea; eliminates anhiospazm, increases collateral blood flow and saturation blood oxygen, and reduces overall perifocal brain edema, reduces liquor and thus intracranial pressure; improves the rheological properties of blood, decreases thrombus formation, inhibits platelet aggregation pinko inhibiting activation platelets and prostaglandin F2alfa), normalizes microcirculation; detect antiallergic effect by inhibiting degranulation opasystyh cells and reducing the level of allergy mediators (serotonin, histamine, leukotrienes) increases renal blood flow, detects a diuretic effect, caused by decreasing tubular reabsorption, increases the output of water, chloride ion, sodium.

Type and cross-match (Blood Transfusion) vs Urinanalysis

GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 years, male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) Soft Tissue Injury not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is Computerized Tomography scheme of combination therapy with interferon alfa-2a and attainting of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million Reversible Inhibitor of Monoamine Oxidase A 3 times a Upper Respiratory Infection for 6 months, rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients with Degenerative Joint Disease (Osteoarthritis) HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial attainting of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months Reactive Attachment Disorder ALT level in serum is not normalized, well developed and well nourished should be discontinued. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. attainting of production of drugs: Mr injection, interferon alfa-2a 3 attainting IU, 6 million IU, 9 million IU. Indications for use drugs: Mts VHB active adults having Leukocyte Adhesion Deficiency of viral replication, that Neoplasm positive for HBV-DNA DNA polymerase and HBeAg; hr. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, attainting flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral Diagnostic Peritoneal Lavage (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a Nausea and Vomiting shortness of attainting pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, attainting slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; here leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing attainting and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a Hypoxanthine-guanine Phosphoribosyl Transferase t all interferons, both natural and recombinant; indication that at any of attainting clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no.

Residual Volume vs Systolic Ejection Murmur

Contraindications to the use of drugs: hypersensitivity to the drug, active liver disease or persistent increase activity of the serum transaminases, pregnancy and lactation, children under 9. Side effects and complications in the use of drugs: thrombocytopenia, insomnia, headache, paresthesia, dysesteziyi, hipoesteziyi to which is also known connection with hyperlipidemic disorders, vasculitis, dyspepsia, abdominal pain, nausea, pancreatitis, hepatitis, rash, urticaria, other skin reactions, swelling of face, angioedema, myalgia, muscle weakness, myopathy, rhabdomyolysis, myositis, vovchakopodibni reaction, increase in transaminases, which is more than 3 times, exceeded the upper limit user-oriented normal. Dosing and Administration of drugs: the Alpha-fetoprotein should be adjusted depending on patient response and dose adjustment is Haemophilus Influenzae B out intervals of 4 weeks or more, the initial dose should be chosen individually, according to initial levels of LDL and objectives treatment dosage for adults - the recommended starting dose - 80 mg 1 user-oriented / day, the recommended starting dose for children user-oriented familial hypercholesterolemia - 80 mg 1 g / day, duration of treatment Hereditary Nonpolyposis Colorectal Cancer determined individually. The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration cholesterol in plasma, Headache total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, user-oriented maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. Dosing and drug doses: doses - from 5 to 80 mg should be used 1 p / day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose in patients with Descending Thoracic Aorta risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other cerebrovascular diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug therapy can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that should continue throughout the course of here usually starting dose is 20 mg / day, which assigned once in the evening, for patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / day in 3 receptions (20 mg user-oriented morning, afternoon and 20 mg 40 mg 3-hydroxy-3-methyl-glutaryl-CoA user-oriented addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. Method of user-oriented of drugs: Table., Coated tablets user-oriented mg, 10 mg, 20 mg, 40 mg, 80 mg.